Prollenium Medical Technologies Inc. announces U.S. FDA approval for its cross-linked hyaluronic acid dermal filler

Prollenium Medical Technologies Inc. announced its United States (U.S.) Food and Drug Administration (FDA) approval for its cross-linked hyaluronic acid dermal filler. Ario Khoshbin, Founder and CEO, stated “This is definitely one of our proudest moments as an organization. FDA approval is a culmination of efforts from every single member of our team. As an organization, we have been working towards this goal from the first day the company opened its doors, and to see it come to fruition is a validation of our vision.  The U.S. market and its potential will be an exciting challenge for our team, but one that will have many rewards for our business both in the U.S. and globally.”